Is ChondroFiller injection right for your hip?

Not every hip cartilage problem is suited to ChondroFiller injection — and understanding the difference matters before anything else.

The treatment is designed for focal, isolated cartilage defects: areas of ICRS Grade III or IV damage measuring roughly 2–6 cm², where the rest of the articular surface and the joint space remain largely intact. The two most common causes in eligible patients are femoroacetabular impingement (FAI) and post-traumatic injury. Typical candidates are active adults in their 40s to mid-60s who have worked through conservative measures without adequate relief.

Where ChondroFiller injection is not appropriate is in diffuse or advanced osteoarthritis. A prospective cohort study by Mazek et al. (2021) followed 26 adults with acetabular cartilage lesions associated with FAI. Patients who already had Tönnis grade 2–3 osteoarthritis at the time of treatment achieved poor results. By contrast, 17 of the 21 evaluable patients with focal defects and preserved joint architecture went on to achieve good or excellent outcomes at three-to-five-year follow-up. The clinical evidence supports that distinction — it is not simply a theoretical line.

Before any injection is planned, a detailed MRI of the hip is mandatory. It maps the exact size, location, and grade of the defect and confirms whether the surrounding cartilage and subchondral bone are appropriate for this approach.

The procedure itself is an outpatient, ultrasound-guided injection — no surgery, no general anaesthetic, no operating theatre.

How ChondroFiller injection works in the hip joint

ChondroFiller is an acellular Type I collagen hydrogel — a CE-marked Class III medical device that contains no donor cells, no harvested tissue, and no biological material from another person. That distinction matters because it changes the therapeutic aim entirely.

Injected as a liquid, the collagen solution encounters body temperature inside the joint and self-polymerises within approximately 3–5 minutes into a firm, three-dimensional scaffold that conforms to the shape of the cartilage defect. Think of it as a temporary framework: it holds the space and provides the biological architecture that the body then builds on.

The scaffold's role is chemotactic. It draws the patient's own progenitor cells — from the surrounding synovium and from the subchondral bone beneath the defect — into its structure. This process is called acellular matrix-induced chondrogenesis. Over roughly 3–6 months, those recruited cells remodel the collagen matrix into fibrocartilage-like repair tissue. As that new tissue matures and stabilises, the original collagen scaffold gradually resorbs — a process that unfolds over 6–24 months — leaving behind the body's own repair material.

Early laboratory evidence supports this sequence. A 2025 osteochondral explant study recorded a 2.4-fold increase in DNA content within the ChondroFiller scaffold by day 14 of culture, consistent with meaningful host-cell recruitment in the initial stages.

This is categorically different from viscosupplementation (hyaluronic acid) or corticosteroid injection. Both of those manage pain and inflammation without addressing the structural defect. ChondroFiller injection targets the lesion itself — the aim is repair tissue, not symptom masking.

Why hip injections need ultrasound guidance

Reaching the hip joint is anatomically more demanding than injecting a superficial structure such as the knee. The joint sits 4–8 cm beneath the skin, and the access corridor runs close to several major structures: the femoral nerve lies approximately 2.3 cm lateral to the capsule, the femoral artery approximately 1.9 cm medial, and the lateral circumflex femoral artery takes a variable course that can place it directly over the anterior capsule. These are not rare anatomical curiosities — they are consistent features of hip anatomy that any injection technique must account for.

The practical consequence is clear in the data. A 2016 systematic review by Hoeber et al. found that landmark-guided hip injections — where the clinician estimates needle position from surface anatomy alone — achieved accurate intra-articular placement in only 72% of cases. Under real-time image guidance, accuracy reached 100% (p<0.0001).

Ultrasound resolves the challenge directly. With a probe positioned over the hip, the clinician sees a live cross-section: the bony contour of the femoral head, the overlying soft-tissue layers, and the joint space itself. The needle tip is tracked continuously on-screen rather than inferred from landmarks. Once the tip is confirmed inside the joint, the clinician can also observe the ChondroFiller gel distributing over the defect site — which matters because the scaffold must polymerise in the correct location to be therapeutically useful.

At the London Cartilage Clinic, ultrasound guidance is the standard pathway for ChondroFiller injection in the hip — not an optional upgrade.

What happens on the day of your ChondroFiller injection

Arriving at the London Cartilage Clinic on Harley Street, patients are seen by Professor Paul Y. F. Lee and need not have fasted, and no general anaesthetic or surgical gown is involved. The room is a standard clinical outpatient space equipped with an ultrasound unit, not an operating theatre.

The skin over the front of the hip is cleaned and a local anaesthetic is injected at the access site. Once the area is numb, Professor Lee positions the ultrasound probe over the hip and the live cross-section appears on-screen — the same imaging picture described in the previous section. The needle is then introduced and advanced under continuous real-time visualisation until the tip is confirmed inside the joint.

With placement confirmed, the ChondroFiller collagen gel is slowly delivered into the defect. The patient remains still for a few minutes while the gel self-sets at body temperature; the scaffold conforms to the defect and holds its position before the needle is withdrawn. No sutures are needed, and there is no incision to close.

After a short rest, the patient is discharged the same day with a pair of crutches. Protected weight-bearing is required for 1–6 weeks to allow the scaffold to integrate without disruption; the clinical team will explain the specific loading protocol before departure. The entire appointment, from arrival to discharge, runs approximately one hour.

Recovery timeline and when to expect results

Crutches for the first one to six weeks are not arbitrary caution — they follow directly from the scaffold's biology. A 2024 biomechanical study tested ChondroFiller under full cyclic loading and found the material has initial mechanical instability at that load level: the scaffold has not yet integrated into the defect wall, and unrestricted weight-bearing at this stage risks displacing it before repair tissue can form. Once stable defect filling is established, graduated loading can begin, guided by the clinical team's protocol.

In the first few days, localised swelling, a transient pain flare, and joint stiffness are common. These are the expected signs of a biological response, not a complication, and they typically settle quickly. Patients who interpret this early discomfort as a sign the treatment has failed will be reassured to know it reflects normal tissue activity around the scaffold.

The more important expectation to set is around timing of meaningful benefit. ChondroFiller injection is not an analgesic — it delivers no immediate pain relief. Functional improvement emerges as recruited progenitor cells remodel the scaffold into repair tissue, a process that unfolds over three to six months. Most of the functional gain then consolidates within the first twelve months, rather than continuing to climb indefinitely.

The clearest quantitative picture of this trajectory comes from knee cohorts, where IKDC scores have risen from a baseline of approximately 48 to approximately 80 at three years — a roughly 30-point gain. Hip-specific trial data are sparser; as noted in the candidacy discussion above, the 2021 Mazek et al. prospective cohort demonstrated meaningful functional improvement in well-selected focal acetabular defect patients at three-to-five-year follow-up, though powered randomised controlled trial data for the hip have not yet been published.

Booking an assessment at the London Cartilage Clinic

For adults with a focal hip cartilage defect — an isolated ICRS Grade III or IV lesion in a joint that still has preserved space and intact surrounding cartilage — a specialist assessment is the natural next step. ChondroFiller injection for hip cartilage damage is available in the UK at the London Cartilage Clinic on Harley Street, the UK's certified centre for this treatment.

An initial assessment covers review of existing MRI or arrangement of imaging if not yet done, evaluation of candidacy against defect size, grade, and osteoarthritis status, and a discussion of the treatment plan. It is a starting point, not a commitment to proceed.

Appointments can be booked at londoncartilage.com.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
3. [3] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759